Filling Tresiba® prescriptions: What you need to know

Tresiba® is a once-daily, long-acting basal insulin indicated to improve glycemic control in adults with diabetes.1    

Tresiba® comes in 2 dose formulations:

U-200 and U-1001

Tresiba® U-200 FlexTouch®: Maximum dose of 160 units per injection (in 2-unit increments)


Tresiba® U-100 FlexTouch®: Maximum dose of 80 units per injection (in 1-unit increments)


Two packages of Tresiba® FlexTouch® samples

Other facts about Tresiba®1:

  • Injected subcutaneously once daily at any time of day
    • Instruct patients who miss a dose of Tresiba® to inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule
    • Instruct patients to ensure that at least 8 hours have elapsed between consecutive Tresiba® injections
    • The recommended time between dose increases is 3 to 4 days
  • No dose conversion needed
    • The dose window for both the Tresiba® U-100 and U-200 pens shows the number of units to be delivered
  • Opened (in-use) Tresiba® FlexTouch® pen may be used for up to 8 weeks, if kept at room temperature below 86ºF (do not refrigerate)
Eligible patients pay no more than $15 per prescriptiona

aFor up to 24 months. Maximum savings of $500 per prescription. Eligibility and other restrictions apply.


Don’t forget to order
NovoFine® Plus disposable needles

Ultra-short, ultra-thin, and designed to resist breaking or bending.b



Tresiba® U-200 FlexTouch®:

Forest green label


Information for Tresiba® FlexTouch® 200 units/mL pen

Concentration

200 units/mL


Pens per package

3


Volume per pen

3 mL


Units of insulin per pen

600 units


Units of insulin per package

1800 units


Max dose per injection

160 units


Dose increment

2 units


NDC number

0169-2550-13



Tresiba® U-100 FlexTouch®:

Spring green label


Information for Tresiba® FlexTouch® 100 units/mL pen

Concentration

100 units/mL


Pens per package

5


Volume per pen

3 mL


Units of insulin per pen

300 units


Units of insulin per package

1500 units


Max dose per injection

80 units


Dose increment

1 unit


NDC number

0169-2660-15

bNeedles are sold separately and may require a prescription in some states.


Dive deeper into Tresiba®


Continued efficacy for your patients even if a dose is delayed or schedules change1

Once-daily Tresiba® was studied at alternating dosing intervals of 8 to 40 hours between doses. Patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1

Tresiba® U-200 FlexTouch®: The only basal insulin with a 160-unit maximum-dose pen1

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Tresiba® (insulin degludec injection) Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.

 

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2015.